Hutchison CA, et al. - In this open-label, phase 2, multicenter, randomized controlled trial (EuLITE), researchers compared the frequency of renal recovery in patients with de novo multiple myeloma, severe acute kidney injury, and myeloma cast nephropathy who received high cutoff hemodialysis (HCO-HD) vs standard high-flux hemodialysis (HF-HD). Participants were recruited from 16 hospitals in the UK and Germany and were stratified by age and center. Bortezomib, doxorubicin, and dexamethasone chemotherapy was used to treat the patients. Follow-up of 2 years was performed. In an intention-to-treat population, the independence from dialysis at 90 days after random allocation to groups (HCO-HD vs HF-HD) was assessed. HCO-HD vs HF-HD did not result in improved clinical outcomes for patients with de novo multiple myeloma and myeloma cast nephropathy who needed hemodialysis for acute kidney injury and who were treated with a bortezomib-based chemotherapy regimen. Proceeding to a phase 3 study for HCO-HD in these patients was not supported.